Scorpius BioManufacturing's VP of Business Development, Steve Lavezoli, was featured in the June 2023 issue of Contract Pharma. Lavezoli shared his expertise on three key trends shaping the CDMO industry in 2023 and beyond:
- Interest in integrated services
- Increase in the percentage of small volume products
- Talent and raw material shortages
Lavezoli joined Scorpius in 2022 with extensive expertise in single-use technologies, drug substance contract manufacturing, and assisting early-stage clinical programs on the path to commercialization.
To read his full commentary on these trends, visit Contract Pharma's "3 Key Trends With Steve Lavezoli."